Frontlight ResearchEarly access
Taking peoplePhase 2
CSX-1004 Effects on Fentanyl-Induced Respiratory Depression
Key facts
- Who runs it
- Cessation Therapeutics Inc.
- Where
- Netherlands1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 24 people, planned
- Started
- 27 Mar 2026
- Expected to end
- 31 May 2027
- Type of study
- Interventional
- Record updated
- 20 March 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Must provide written informed consent prior to the initiation of any protocol-specific procedures
- Male and female adults, between 18 and 55 years of age, inclusive
- Body mass index (BMI) within 18.0 to 32.0 kg/m², inclusive (minimum weight of at least 50.0 kg)
- Must be medically stable, as determined by medical history, physical examination, ECG, and vital signs at Screening
- Negative urine drug screen for fentanyl at Screening
- Is willing and able to comply with the study requirements, including clinic confinement and blood sampling
- Part B: Diagnosis of mild or moderate opioid use disorder (DSM-5-TR) and self-reported daily opioid use, defined as daily oral MME doses ≥30 to ≤120 mg for at least 3 months
Who cannot take part
- Requires concomitant treatment with prohibited medications that cannot be safely discontinued prior to first drug administration
- History or presence of any clinically significant psychiatric, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, renal, or other major disease or illness at Screening
- Part A: History of or currently meets the criteria for a diagnosis of substance use disorder according to DSM-5-TR criteria for any substances (excluding caffeine)
- Part B: Currently meets the criteria for a diagnosis of substance use disorder according to DSM-5-TR criteria for any substances, excluding opioids, caffeine, or nicotine
- Part B: History of or currently meets the criteria for a diagnosis of severe opioid use disorder
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the effect of CSX-1004 Injection on fentanyl-induced respiratory depression in healthy adult participants and participants with OUD, as determined by change in isohypercapnic minute ventilation (MV).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Randomized, Single-Blind, Fixed-Order Crossover Study to Assess the Effects of CSX-1004 Injection on Fentanyl-Induced Respiratory Depression in Healthy Adult Subjects and Subjects with Opioid Use Disorder
- Fit questions
- Built from 2025-524133-33-00, who can take part
- Record updated
- 20 March 2026